NCT07465276
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07465276
Title Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Dana-Farber Cancer Institute
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA